Research and Markets: Daiichi Sankyo Co., Ltd: PharmaVitae Profile Examines their...

Research and Markets: Daiichi Sankyo Co., Ltd: PharmaVitae Profile Examines their Historical and Forecast Performance in the Ethical Pharma Sector

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c81974) has announced the
addition of "Daiichi Sankyo Co., Ltd: PharmaVitae Profile" to their
offering.

This analysis examines the historical and forecast performance for
Daiichi Sankyo in the ethical pharma sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and
assessment of financial performance, with 1-6 year sales forecasts for
key drugs. An interactive forecasting and analysis tool provides
continually updated quantitative and qualitative information.

Key reasons to purchase this title

-- Benchmark Daiichi Sankyos performance against key rivals in
the ethical pharmaceutical sector

-- See how the continued success of Daiichis olmesartan
antihypertensives franchise (Benicar, Benicar HCT and Azor) is
central to the companys outlook

-- Evaluate the prospects of the companys key pipeline candidate,
prasugrel, which is being co-developed with Eli Lilly

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 CORPORATE HISTORY

CHAPTER 3 HISTORICAL PERFORMANCE

CHAPTER 4 FORECAST PERFORMANCE

CHAPTER 5 KEY PRODUCTS AND COMPETITORS

CHAPTER 6 APPENDIX

Companies mentioned:

- ACS Motion Control Ltd

- Astellas Pharma

- AstraZeneca PLC

- Automatic Data Processing, Inc.

- Bristol-Myers Squibb Company

- Chugai Pharmaceutical Co. Ltd

- CuraGen Corporation

- Daiichi Sankyo, Ltd.

- Dainippon Sumitomo Pharma Co., Ltd.

- Eli Lilly and Company

- Forest Laboratories, Inc

- IMS Health

- Merck & Co., Inc.

- Novartis AG

- Pfizer Inc

- Santen Pharmaceutical Co., Ltd.

For more information visit
here

Source: Datamonitor

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

Copyright Business Wire 2008